Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Danaher Corporation (NYSE: DHR) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8‑K, quarterly reports on Form 10‑Q and other disclosures that detail Danaher’s financial performance, governance changes and capital markets activities as a global life sciences and diagnostics innovator.
Danaher uses Form 8‑K filings to report material events such as quarterly and annual financial results, estimated financial performance ahead of investor conferences, amendments to its by‑laws, share repurchase authorizations and changes in senior leadership or board composition. For example, the company has filed 8‑Ks to furnish earnings press releases and presentation slides, to describe updates to its by‑laws regarding shareholder proposal and nomination procedures, and to outline a share repurchase program authorizing the repurchase of up to 35 million shares of common stock.
The filings also list Danaher’s securities registered under Section 12(b) of the Exchange Act, including its common stock and multiple series of senior notes with various maturities, all traded on the New York Stock Exchange. This information helps investors understand the company’s capital structure and the instruments available in public markets.
Through its periodic reports, Danaher provides detailed financial statements, management’s discussion and analysis, and explanations of non‑GAAP measures such as core sales growth and adjusted diluted net earnings per common share. The company explains how it calculates these measures, why management uses them and how they reconcile to the most directly comparable GAAP figures, including adjustments for amortization of acquisition‑related intangible assets, fair value gains and losses on investments, impairments and tax effects.
On Stock Titan, users can review these SEC filings alongside AI‑powered summaries that highlight key points, such as revenue trends, margin drivers, capital allocation decisions, governance changes and risk disclosures. The platform’s tools can help readers quickly understand the implications of Danaher’s 10‑Q and 10‑K reports, as well as 8‑K items related to dividends, share repurchases, executive transitions and by‑law amendments, while still allowing detailed review of the original documents.
Danaher Corporation executive Gregory M. Milosevich reported a small tax-related share disposition. On February 24, 2026, he transferred 189 shares of common stock at a reported price of $209.19 per share to satisfy tax withholding obligations. After this transaction, he directly holds 4,910 common shares.
Danaher Corporation executive Julie A. Sawyer Montgomery reported a tax-related share disposition. On February 24, 2026, she disposed of 372 shares of Danaher common stock at a price of $209.19 per share to satisfy tax withholding obligations. After this transaction, she directly owned 17,129 shares.
Danaher Corporation Executive Vice President Christopher Paul Riley disposed of 242 shares of common stock on a tax-withholding basis. The shares were transferred at $209.19 per share to cover tax obligations, rather than as an open-market sale. After this transaction, he directly holds 15,343 shares of Danaher common stock.
Danaher Corporation files its 2025 annual report detailing a global portfolio focused on biotechnology, life sciences and diagnostics, organized into three main segments. The company emphasizes recurring-revenue lab and clinical products sold largely through direct sales across about 50 countries.
The filing highlights strategic priorities of applying the Danaher Business System, disciplined capital allocation and talent development, supported by more than 60,000 employees. It discusses a pending acquisition of Masimo Corporation, extensive R&D collaborations, and significant international exposure, with about 59% of 2025 sales from customers outside the U.S., including 11% from China.
Danaher outlines broad risk factors: economic and healthcare reimbursement pressures, intense competition and rapid technology change, supply-chain and cybersecurity vulnerabilities, regulatory and environmental obligations, AI-related uncertainties, and challenges tied to global operations and government policies. Human capital, safety, sustainability and regulatory compliance are presented as central to long‑term performance.
Danaher Corporation Executive Vice President Gregory M. Milosevich exercised employee stock options covering 1,320 shares on February 19, 2026, converting them into common stock at an exercise price of $58.5900 per share. On the same day, he sold 1,320 common shares at $208.0110 per share, leaving him with 5,099 directly owned shares. The options had vested in five equal annual installments from their original grant date, as disclosed in the footnote.
Danaher Corporation has agreed to acquire Masimo Corporation, a specialty diagnostics and patient monitoring company, in an all-cash deal. Danaher will pay $180 per Masimo share, implying a total enterprise value of about $9.9 billion including assumed debt and net of acquired cash.
The price represents roughly an 18x multiple of Masimo’s estimated 2027 EBITDA, or about 15x when including the full benefit of expected annual synergies. Masimo is expected to generate more than $530 million of EBITDA in 2027, with over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year after closing.
Danaher expects the deal to add $0.15–$0.20 to adjusted diluted EPS in the first full year and about $0.70 by the fifth year. Masimo will operate as a standalone business within Danaher’s Diagnostics segment. The transaction is anticipated to close in the second half of 2026, funded with cash on hand and new debt, and remains subject to Masimo stockholder approval and customary regulatory clearances, including U.S. and non-U.S. antitrust and foreign investment reviews.
Danaher Corporation reported that director Jessica L. Mega has retired from its Board of Directors effective February 5, 2026. She stepped down because of commitments related to her other professional obligations.
The company stated that Dr. Mega’s decision was not due to any disagreement with Danaher regarding its operations, policies, or practices, indicating an orderly and amicable board transition.
Danaher Corporation Executive Vice President Christopher Paul Riley acquired 1,046 shares of common stock on February 4, 2026 at a price of $0 per share. The shares were delivered upon achievement of performance criteria for performance stock units granted on February 24, 2023 under the Danaher Corporation 2007 Omnibus Incentive Plan.
The award remains subject to a holding period that continues through December 31, 2027. Following this transaction, Riley directly beneficially owns 15,585 shares of Danaher common stock.
Danaher Corporation reported that Senior Vice President Brian W. Ellis acquired 1,695 shares of common stock on February 4, 2026. The shares were issued at $0 per share following the Compensation Committee’s determination that performance criteria from a February 24, 2023 performance stock unit award were achieved under the Danaher Corporation 2007 Omnibus Incentive Plan.
After this award, Ellis directly holds 14,994 shares of Danaher common stock. The award remains subject to a holding period that continues through December 31, 2027, meaning the shares must be held until at least that date.